Clinical Trial Update: Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

View source ↗

Summary

Ongoing clinical trial evaluating pyrotinib combined with trastuzumab for maintenance therapy in HER2-positive breast cancer after first-line therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tyvyt (Sintilimab)

Snippet

Sponsor: zhangjie | Conditions: HER2-positive Breast Cancer | Status: RECRUITING